HBV-IN-8 is a potent HBV inhibitor with an EC50 of 287.9 nM (WO2021213445A1, compound 13).

Glyasperin C is a potent and reversible noncompetitive inhibitor of neuraminidase with an IC50 of 20% at 200 μM. Glyasperin C is a polyphenol isolated from the roots of Glycyrrhiza uralensis.

HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC50 of 0.46 µM (From patent WO2018085619A1, example 28).

MAO A/HDAC-IN-1 is a dual inhibitor of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research.

GPBAR1-IN-3 (Compound 14) is a selective GPBAR1 agonist (EC50=0.17 μM) and a CysLT1R antagonist.

LW479, a novel HDAC inhibitor, could be a candidate drug for breast cancer prevention.

1-Methoxyphaseollidin, a flavonoid compound, is a lysoPAF acetyltransferase inhibitor, with an IC50 of 48 μM. 1-Methoxyphaseollidin exhibits anti-H.pylori activity against the CLAR and AMOX-resistant strain as well as four CLAR (AMOX)-sensitive strains.

ATR-IN-7 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-7 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021238999A1, compound 1).

SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).

NSC 828467 exhibited significant in vitro anticancer activity,and it is one of the top-five CA IX inhibitors with an IC50 value of 27.2nM.

ME-143 is a second-generation tumor-specific inhibitor of NADH oxidase. ME-143 inhibits the WNT/β-catenin pathway in colorectal cancer cells. ME-143 has broadly active against cancers in vitro and in vivo.

GDC-4379 is a JAK1 inhibitor that can be used for the research of asthma.

(Z)-Fluoxastrobin is fungicide agent. (Z)-Fluoxastrobin has excellent control of important seed and soilborne pathogens.

MPGES-1 is considered as a promising therapeutic target of the next generation anti-inflammatory drugs in the treatment of inflammatory diseases. The < b > IC < sub > 50 < / sub > < / b > value of mPGES-1-IN-1 is 0.03 μ M。

BRD4-BD1/2-IN-1 is a potent BRD4 inhibitor with IC50s of <100 nM for BRD4 BD-1 and BRD4 BD-2, respectively (US20150148375A1, compound 5).

L-Serine-13C ((-)-Serine-13C) is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.

L-Serine-2-13C ((-)-Serine-2-13C) is the 13C-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.

L-Cysteine-1-13C is the 13C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.

L-Cysteine-3-13C is the 13C-labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.

L-Alanine-3-13C (L-2-Aminopropionic acid-3-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

L-Alanine-2-13C (L-2-Aminopropionic acid-2-13C) is the 13C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

DL-Alanine-3-13C is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver.

DL-Alanine-1-13C is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver.

L-Serine1-13C,15N ((-)-Serine-13C,15N) is the 13C- and 15N-labeled L-Serine. L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.

L-Alanine-1-13C,15N (L-2-Aminopropionic acid-1-13C,15N) is the 13C- and 15N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

L-Aspartic acid-1,4-13C2 is the 13C-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.

L-Aspartic acid-1,4-13C2,15N is the 13C- and 15N-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable prodrug for colon-specific drug deliverly.

Ethyl linoleate-13C18 (Linoleic Acid-13C18 ethyl ester) is the 13C labeled Ethyl linoleate. Ethyl linoleate inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.

Eosin Y is a dye molecule. Eosin Y has low cost and good availability which has a wide application in organic synthesis as a photoredox catalyst.

Paecilaminol (FKI-0550) is potent NADH-fumarate reductase inhibitor. Paecilaminol exhibits an IC50 value of 5.1 μM against Ascaris suum NADH-fumarate reductase.